NEW YORK, May 16, 2022 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company”), a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that the registration statement on Form S-3, filed on May 4, 2022was declared effective by the U.S. Securities and Exchange Commission, which includes a prospectus for a market offering of shares pursuant to which the Company may offer and sell its Subordinated Voting Shares or Redesignated Common Shares of the Subordinated Voting Shares of the Company (collectively, the “shares”) for up to $100,000,000 in aggregate sales proceeds on “in-market” transactions (the “ATM Program”).
Distributions of shares under the ATM Program will be made pursuant to the terms of an equity offering sales agreement entered into with brokers Cantor Fitzgerald & Co., and Oppenheimer & Co. Inc. The volume and timing of distributions under the ATM Program, if any, will be determined in the sole discretion of the Company. Shares will be distributed at prevailing market prices at the time of each sale and, accordingly, prices may vary between purchasers and over the life of the ATM Program. The ATM Program will be effective until the issuance and sale of all shares issued pursuant to the ATM Program and the end of the effective period of the Registration Statement on Form S-3 (File No. 333-264648), which which happens first. unless terminated prior to such date by the Company or its agents in accordance with the terms of the stock offering sale agreement. No offer or sale of shares under the ATM Program will occur in Canada or a person residing in Canada.
The securities described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (the “SEC”), which the SEC declared effective on May 16, 2022. Copies of the prospectus relating to the ATM Program may be obtained from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, NY 10022; email: email@example.com, or Oppenheimer & Co. Inc., 85 Broad Street, 26th Floor, New York, NY 10004, Attn: Syndicate Prospectus Department, Phone: (212) 667-8055 or Email: EquityProspectus@opco.comor by accessing the SEC’s website, www.sec.govor on SEDAR at www.sedar.com.
This news release will not constitute an offer to sell or the solicitation of an offer to buy the shares, nor will there be any sale of the shares in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to filing. or qualification under the securities laws of such state or other jurisdiction.
About Mind Med
MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain, and neurology. The company is developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed is listed on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the MMED symbol.
Certain statements in this press release relating to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are forward-looking in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events, and is therefore subject to risks and uncertainties that could cause actual results to differ materially from future results expressed or implied in forward-looking statements. . These statements can generally be identified by the use of forward-looking words such as “will”, “could”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”. “, “believe”, “potential” or “continue”, or the denial of the same or similar variations. Forward-looking information in this press release includes, but is not limited to, statements regarding possible sales of shares in accordance with the The Company’s ATM Program There are numerous risks and uncertainties that could cause the Company’s plans and objectives to differ materially from those expressed in forward-looking information, such as the risks discussed or mentioned in this document and the risks described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and your Quarterly Report on Form 10-Q for the period ended March 31, 2022 under headings such as “Special Note Regarding Forward-Looking Statements” and “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other filings and documents made by the Company with regulatory authorities in values in all provinces and territories of Canada which are available on the Company’s profile on SEDAR at www.sedar.com and with the US Securities and Exchange Commission on EDGAR at www.sec.gov. Except as required by law, the Company assumes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.
For media: firstname.lastname@example.org
For investors: email@example.com
SOURCE Mental Medicine (MindMed) Inc.
See original content for media download: http://www.newswire.ca/en/releases/archive/May2022/16/c2606.html